MASI.NASDAQMasimo CORP

DEFA14A: Masimo Accuses Politan of Misleading Statements Ahead of Stockholder Vote

Sentiment:

Definitive Additional Materials


Masimo claims Politan Capital Management and Quentin Koffey made false and misleading statements to stockholders regarding key issues like the spin-off, board's role in the sale process, and the outcome of the sale process.

Summary

  • Masimo issued a press release addressing alleged false and misleading statements made by Politan Capital Management and Quentin Koffey.
  • The company claims Politan lied about the spin-off, the board's role in the sale process, and the outcome of the sale process.
  • Masimo urges stockholders to vote for their director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card.
  • Masimo highlights its commitment to separating the consumer business and expanding the board with independent directors.
  • The company warns that if Politan gains control, CEO Joe Kiani and COO Bilal Muhsin may resign, and over 300 employees may follow suit.
  • The 2024 Annual Meeting is scheduled for September 19, 2024.

Sentiment

Score: 4

Explanation: The sentiment is somewhat negative due to the ongoing proxy battle and accusations of misleading statements. The potential for key personnel resignations also contributes to the lower score.

Positives

  • Masimo is actively defending itself against what it perceives as misleading information.
  • Masimo is highlighting its plans to separate the consumer business and expand the board with independent directors.

Negatives

  • The press release indicates a contentious proxy battle with Politan Capital Management.
  • There is a risk of key personnel resignations if Politan gains control of the board.
  • The company had to issue corrective disclosures due to Politian's actions.

Risks

  • Uncertainties regarding future actions that may be taken by Politan.
  • Potential cost and management distraction attendant to Politans nomination of director nominees at the 2024 Annual Meeting.
  • The risk that Masimo's expectations regarding its future performance and governance changes may not be realized.

Future Outlook

The company discusses potential stockholder approval of the Boards nominees, changes to Masimo's governance, including the composition of Masimo's Board of Directors and Masimo's plans to expand the Board; and the proposed separation of Masimos consumer business, including any potential joint venture or any other potential separation of Masimos consumer business.

Management Comments

  • Masimo issued the following statement: Politan and Quentin Koffey have relied on misleading and false statements to distract both stockholders and proxy advisory firms from their lack of a plan or strategy for Masimo.
  • Masimo's COO, Bilal Muhsin, has also declared his intent to resign if Politan gains control of the Board, and more than three hundred other employees, including senior executives, have expressed that they may follow suit.

Industry Context

This announcement reflects a proxy battle, which is not uncommon in the corporate world when activist investors seek to influence company strategy or governance. The outcome of the vote could significantly impact Masimo's future direction.

Legal Proceedings

  • Masimos lawsuit forced Politan to issue several new disclosures, including on the morning of the hearing, to correct its false and misleading statements and to provide material information Politan previously concealed from Masimo stockholders, ISS and Glass Lewis.

Stakeholder Impact

  • The outcome of the proxy vote will impact shareholders, employees, and potentially customers if there are significant changes in strategy or leadership.

Next Steps

  • Stockholders are urged to vote on the updated GOLD proxy card.
  • The outcome of the vote at the September 19, 2024 Annual Meeting will determine the composition of Masimo's board.

Key Dates

DateDescription
1995Introduction of Masimo SET Measure-through Motion and Low Perfusion pulse oximetry.
2005Masimo introduced rainbow Pulse CO-Oximetry technology.
2013Masimo introduced the Root Patient Monitoring and Connectivity Platform.
August 12, 2024New record date for the 2024 Annual Meeting.
August 15, 2024The Company filed a revised version of its 2024 proxy statement.
August 22, 2024The Company filed a revised version of the Revised Proxy Statement with the SEC.
September 12, 2024Masimo issued a press release regarding Masimos 2024 Annual Meeting of Stockholders.
September 19, 2024Masimos 2024 Annual Meeting of Stockholders.

Keywords

Masimo, Politan Capital Management, Proxy Contest, Stockholders, Director Nominees, Annual Meeting, False Statements, Governance, Spin-off

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.